Babamohamadi Zahra, Taherkhani Amirreza, Yousefzadeh Ali, Moradi Ali, Heidari Marziyeh, Hoseini Nasab Zahra Sadat, Haghi Seyedeh Mona, Afkhami Ayda, Belbasi Mohaddeseh, Noroozi Masoud, Deravi Niloofar
Hearing Disorders Research Center, Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Student Research Committee, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Front Oncol. 2025 Apr 2;15:1534343. doi: 10.3389/fonc.2025.1534343. eCollection 2025.
Salivary gland carcinoma (SGC) is an infrequent malignancy characterized by various pathological subtypes. Immune checkpoint inhibitors (ICIs) have emerged as promising therapeutic strategies for several cancers. Evidence suggests that ICIs may be effective against rare neoplasms, including SGC. This meta-analysis evaluated the efficacy of programmed death-1 (PD-1) and programmed death ligand 1 (PD-L1) inhibitors in treating salivary gland cancers.
A thorough search was conducted in PubMed, Scopus, and Google Scholar databases up to 24 February 2024. The title, abstract, and full text of related articles were extracted and screened, and the quality of the included articles was assessed. The data extracted were then analyzed. The research protocol of this systematic review and meta-analysis was registered on the PROSPERO website.
Altogether, a total of five cohort studies and three randomized controlled trials (RCTs) with a total population of 532 were included in these meta-analyses. These studies were conducted in the USA, Japan, France, and China. The average age of the patients was between 53 and 67 years. Our analyses showed an increase in progression-free survival in the cohort studies and RCTs, and the pooled effect is 1.12 (95% CI 1-1.25) and 1.14 (95% CI 1.07-1.20), respectively, in patients with SGC who received PD-1 and PD-L1 inhibitors.
This meta-analysis suggests that PD-1 and PD-L1 inhibitors in patients with salivary gland cancer can significantly increase progression-free survival. Due to the high heterogeneity of the studies, more RCTs with a larger sample size are required to prove the association.
涎腺癌（SGC）是一种罕见的恶性肿瘤，具有多种病理亚型。免疫检查点抑制剂（ICIs）已成为几种癌症有前景的治疗策略。有证据表明，ICIs可能对包括SGC在内的罕见肿瘤有效。本荟萃分析评估了程序性死亡-1（PD-1）和程序性死亡配体1（PD-L1）抑制剂治疗涎腺癌的疗效。
截至2024年2月24日，在PubMed、Scopus和谷歌学术数据库中进行了全面检索。提取并筛选相关文章的标题、摘要和全文，并评估纳入文章的质量。然后对提取的数据进行分析。本系统评价和荟萃分析的研究方案已在PROSPERO网站上注册。
这些荟萃分析共纳入了5项队列研究和3项随机对照试验（RCT），总样本量为532。这些研究在美国、日本、法国和中国进行。患者的平均年龄在53至67岁之间。我们的分析显示，队列研究和RCT中无进展生存期有所增加，接受PD-1和PD-L1抑制剂的SGC患者的合并效应分别为1.12（95%CI 1-1.25）和1.14（95%CI 1.07-1.20）。
本荟萃分析表明，PD-1和PD-L1抑制剂可显著提高涎腺癌患者的无进展生存期。由于研究的高度异质性，需要更多样本量更大的RCT来证实这种关联。
Zotero 插件
